{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T14:12:31Z","timestamp":1795270351590,"version":"4.10.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    There is an unmet need for effective and safe treatments for patients with metastatic gastric\/gastroesophageal junction (mG\/GEJ) adenocarcinoma. Targeting claudin 18 isoform 2 (CLDN18.2) and programmed death ligand 1 (PD-L1), represents a promising strategy. Zolbetuximab, a CLDN18.2-targeting antibody, plus chemotherapy improved survival outcomes in patients with CLDN18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative mG\/GEJ adenocarcinoma. Cohort 4 of the global, open-label, phase 2 ILUSTRO study examined first-line zolbetuximab plus mFOLFOX6 and nivolumab (a PD-L1 inhibitor). Here we report results from cohorts 4A (safety lead-in phase) and 4B (expansion phase). The primary endpoint of ILUSTRO was specific to cohort 1 and was previously published; the main efficacy endpoint of interest for cohort 4 was progression-free survival (PFS), as assessed by the investigators per Response Evaluation Criteria in Solid Tumors version 1.1. At data cutoff (2 September 2025) for this final analysis, 77 patients were enrolled in 4A\u2009+\u20094B (85.5% with CLDN18.2-high tumors). Cohort 4B median follow-up was 11.5\u2009months, and median PFS (95% confidence interval (CI)) was 14.8\u2009months (8.3\u2013not estimable) overall (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200971) and 18.0\u2009months (11.1\u2013not estimable) in patients with CLDN18.2-high tumors (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200959). Objective response rate (measurable disease; 95% CI) was 62.1% (48.4\u201374.5) in 4B overall (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200958) and 68.1% (52.9\u201380.9) in CLDN18.2-high (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200947). In 4A\u2009+\u20094B, the most common treatment-emergent adverse events were nausea (80.5%) and decreased appetite (72.7%). Efficacy and safety data support randomized evaluation of zolbetuximab plus chemoimmunotherapy in patients with CLDN18.2-positive and PD-L1-positive mG\/GEJ adenocarcinoma in the ongoing phase 3 LUCERNA study. ClinicalTrials.gov:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03505320\" ext-link-type=\"uri\">NCT03505320<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04306-9","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T10:02:03Z","timestamp":1773655323000},"page":"2182-2190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":false,"given":"Kohei","family":"Shitara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8491-703X","authenticated-orcid":false,"given":"Keun-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Metges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Matsangou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archita","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5095-8283","authenticated-orcid":false,"given":"Miaomai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2512-1661","authenticated-orcid":false,"given":"Jason","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-5653","authenticated-orcid":false,"given":"Aziz","family":"Zaanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4062-0808","authenticated-orcid":false,"given":"Samuel J.","family":"Klempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"4306_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"4306_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27\u201340 (2021).","journal-title":"Lancet"},{"key":"4306_CR3","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1158\/1078-0432.CCR-23-0204","volume":"29","author":"SJ Klempner","year":"2023","unstructured":"Klempner, S. J. et al. ILUSTRO: phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma. Clin. Cancer Res. 29, 3882\u20133891 (2023).","journal-title":"Clin. Cancer Res."},{"key":"4306_CR4","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu, M. Z. et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ 385, e078876 (2024).","journal-title":"BMJ"},{"key":"4306_CR5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181\u20131195 (2023).","journal-title":"Lancet Oncol."},{"key":"4306_CR6","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 29, 2133\u20132141 (2023).","journal-title":"Nat. Med."},{"key":"4306_CR7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","volume":"31","author":"L Shen","year":"2025","unstructured":"Shen, L. et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat. Med. 31, 1163\u20131170 (2025).","journal-title":"Nat. Med."},{"key":"4306_CR8","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401, 1655\u20131668 (2023).","journal-title":"Lancet"},{"key":"4306_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","volume":"393","author":"K Shitara","year":"2025","unstructured":"Shitara, K. et al. Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer. N. Engl. J. Med. 393, 336\u2013348 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4306_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer Association.","year":"2023","unstructured":"Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer 26, 1\u201325 (2023).","journal-title":"Gastric Cancer"},{"key":"4306_CR11","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick, F. et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1005\u20131020 (2022).","journal-title":"Ann. Oncol."},{"key":"4306_CR12","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannova","year":"2022","unstructured":"Obermannova, R. et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 992\u20131004 (2022).","journal-title":"Ann. Oncol."},{"key":"4306_CR13","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(25)00052-2","volume":"405","author":"R Sundar","year":"2025","unstructured":"Sundar, R. et al. Gastric cancer. Lancet 405, 2087\u20132102 (2025).","journal-title":"Lancet"},{"key":"4306_CR14","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/cac2.12193","volume":"41","author":"FH Wang","year":"2021","unstructured":"Wang, F. H. et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun. (Lond.) 41, 747\u2013795 (2021).","journal-title":"Cancer Commun. (Lond.)"},{"key":"4306_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600, 727\u2013730 (2021).","journal-title":"Nature"},{"key":"4306_CR16","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJMc2409512","volume":"391","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma. N. Engl. J. Med. 391, 1159\u20131162 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4306_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","volume":"23","author":"JA Ajani","year":"2025","unstructured":"Ajani, J. A. et al. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J. Natl Compr. Canc. Netw. 23, 169\u2013191 (2025).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"4306_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama, I. et al. Claudin 18.2 as a novel therapeutic target. Nat. Rev. Clin. Oncol. 21, 354\u2013369 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4306_CR19","doi-asserted-by":"crossref","unstructured":"Pellino, A. et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J. Pers. Med. 11, 1095 (2021).","DOI":"10.3390\/jpm11111095"},{"key":"4306_CR20","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin, U. et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin. Cancer Res. 14, 7624\u20137634 (2008).","journal-title":"Clin. Cancer Res."},{"key":"4306_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","volume":"100","author":"U Sahin","year":"2018","unstructured":"Sahin, U. et al. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur. J. Cancer 100, 17\u201326 (2018).","journal-title":"Eur. J. Cancer"},{"key":"4306_CR22","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","volume":"30","author":"O Tureci","year":"2019","unstructured":"Tureci, O. et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann. Oncol. 30, 1487\u20131495 (2019).","journal-title":"Ann. Oncol."},{"key":"4306_CR23","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","volume":"27","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer 27, 1058\u20131068 (2024).","journal-title":"Gastric Cancer"},{"key":"4306_CR24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1200\/JCO.2023.41.4_suppl.466","volume":"41","author":"DM Moran","year":"2023","unstructured":"Moran, D. M. et al. Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G\/GEJa) treated with zolbetuximab. J. Clin. Oncol. 41, 466\u2013466 (2023).","journal-title":"J. Clin. Oncol."},{"key":"4306_CR25","doi-asserted-by":"publisher","first-page":"S559","DOI":"10.1016\/j.annonc.2022.07.069","volume":"33","author":"T Nakayama","year":"2022","unstructured":"Nakayama, T. et al. 42P Antitumor activity of zolbetuximab combined with chemotherapy and anti-mouse PD-1 antibody (anti-mPD-1) in a syngeneic mouse model and a virtual preclinical trial using a quantitative systems pharmacology (QSP) model. Ann. Oncol. 33, S559\u2013S560 (2022).","journal-title":"Ann. Oncol."},{"key":"4306_CR26","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin, U. et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann. Oncol. 32, 609\u2013619 (2021).","journal-title":"Ann. Oncol."},{"key":"4306_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s10120-024-01566-7","volume":"28","author":"HD Kim","year":"2025","unstructured":"Kim, H. D. et al. Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression. Gastric Cancer 28, 74\u201382 (2025).","journal-title":"Gastric Cancer"},{"key":"4306_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104000","volume":"9","author":"TY Kim","year":"2024","unstructured":"Kim, T. Y. et al. Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer. ESMO Open 9, 104000 (2024).","journal-title":"ESMO Open"},{"key":"4306_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251369042","volume":"17","author":"F Zhang","year":"2025","unstructured":"Zhang, F. et al. Impact of claudin 18.2 expression on treatment outcomes of first-line immunochemotherapy in patients with HER2-negative, proficient MMR, PD-L1 CPS \u2265 1 metastatic gastric\/gastroesophageal junction cancer. Ther. Adv. Med. Oncol. 17, 17588359251369042 (2025).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"4306_CR30","doi-asserted-by":"crossref","unstructured":"Klempner, S. J. et al. Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND\/UCLA modified Delphi panel study. ESMO Gastrointest. Oncol. 7, 100131 (2025).","DOI":"10.1016\/j.esmogo.2024.100131"},{"key":"4306_CR31","doi-asserted-by":"crossref","unstructured":"Shitara, K. S. et al. Impact and effective management of nausea\/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies. ESMO Open 11, 105931 (2026).","DOI":"10.1016\/j.esmoop.2025.105931"},{"key":"4306_CR32","doi-asserted-by":"crossref","unstructured":"Cavaletti, G. & Marmiroli, P. Management of oxaliplatin-induced peripheral sensory neuropathy. Cancers (Basel) 12, 1370 (2020).","DOI":"10.3390\/cancers12061370"},{"key":"4306_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s13046-021-02141-z","volume":"40","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development. J. Exp. Clin. Cancer Res. 40, 331 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"4306_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1\u2014update and clarification: from the RECIST committee. Eur. J. Cancer 62, 132\u2013137 (2016).","journal-title":"Eur. J. Cancer"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04306-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04306-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04306-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:03:31Z","timestamp":1781791411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04306-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4306"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04306-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.S. reports receiving personal fees for consulting and advisory roles from Bristol Myers Squibb, Takeda Pharmaceutical, Ono Pharmaceutical, Novartis, Daiichi-Sankyo, Amgen, Boehringer Ingelheim, Merck Pharmaceutical, Astellas Pharma, Guardant Health Japan, Janssen, AstraZeneca, Zymeworks Biopharmaceuticals, ALX Oncology, Bayer, GlaxoSmithKline K.K., HEALIOS K.K., Moderna, Arcus Biosciences, AbbVie, CMIC Co., Ltd., Elevation Oncology, Oncolys BioPharma, Sanofi, Suzuhou Lingyhui Network Technology, Gilead Science, eChinaHealth, Leap Therapeutics, Phans Therapeutics, Scandion Oncology and Revolution Medicines; receiving honoraria from Bristol Myers Squibb, Ono Pharmaceutical, Janssen, Eli Lilly, Astellas Pharma and AstraZeneca; and receiving research funding (all to the institution) from Astellas Pharma, Ono Pharmaceutical, Daiichi-Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical Co., Merck Pharmaceutical, Amgen, Eisai, PRA Health Sciences, Syneos Health, AstraZeneca, PPD-SNBL K.K. TORAY, Incyte Biosciences G.K. and Medpace Japan K. H.S. reports research funding to the institution from Merck Sharp & Dohme, Astellas Pharma, AstraZeneca, AbbVie, Taiho Pharmaceutical, Daiichi-Sankyo, Ono Pharmaceutical, Elevation Oncology, Chugai Pharmaceutical Co. and Metagen Therapeutics. N.F. is an invited speaker for Novartis, Astellas Pharma and Ibsen; has participated on advisory boards for Astellas Pharma, Esteve, Ipsen, ITM, Novartis, Merck Sharp & Dohme and Merck; has an unpaid leadership role with ESMO NET Faculty, ENETS president elect and SPARC Europe steering committee; and is a local principal investigator, with payment to the institution, for Astellas Pharma, Ipsen, Revolution Medicines, ITM and Merck Sharp & Dohme. S.L. reports personal honoraria as invited speaker from Amgen, AstraZeneca, Bristol Myers Squibb, Incyte, GlaxoSmithKline, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Pierre Fabre, Roche and Servier and fees for participation on advisory boards for Amgen, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, GlaxoSmithKline, Incyte, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Servier, Takeda Pharmaceutical, Rottapharm, BeiGene, Fosum Pharma and Nimbus Therapeutics. K.-W.L. reports research funding to the institution from Astellas Pharma; grants or contracts as research funding to the institution for conducting clinical trials from Merck Sharp & Dohme, Ono Pharmaceutical, Merck KGaA, ALX Oncology, BeiGene, Daiichi-Sankyo, Taiho Pharmaceutical, Bolt Biotherapeutics, Trishula Therapeutics, InventisBio, Leap Therapeutics, MedPacto, Ildong Pharmaceutical, Roche, Amgen, Genome & Company, Arcus Biosciences, Jazz Pharmaceuticals, Exelixis, IgM Biosciences, GlaxoSmithKline, Panolos Bioscience, Metafines, Wellmarker Bio, Medicenna, Erasca, Hanmi, AstraZeneca, Torl Biotherapeutics, Bayer, Boehringer Ingelheim, Pfizer, Yuhan, Avelos Therapeutics, IDRx and Jiangsu Hengrui Pharmaceuticals; consulting fees from Astellas Pharma, Daiichi-Sankyo, Merck Sharp & Dohme, Ono Pharmaceutical, BeiGene, AbbVie, Takeda Pharmaceutical, Metafines and Pin Therapeutics; payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from Astellas Pharma, Ono Pharmaceutical, Bayer, Merck Sharp & Dohme, Merck KGaA and Celltrion; and participation on a data safety monitoring board or an advisory board for ALX Oncology (uncompensated). L.-Y.B. reports honoraria from Ono Pharmaceutical, Ipsen, the Taiwan Society for Therapeutic Radiology and Oncology and TTY Biopharm; has a consulting or advisory role with Amgen and Astellas Pharma; and receives research funding from Eisai. K.Y. reports payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from Daiichi-Sankyo, Chugai Pharmaceutical Co., Bristol Myers Squibb K.K., Eli Lilly Japan K.K., Taiho Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceutical, Merck Biopharm and Astellas Pharma. J.-P.M. reports consulting fees from BeiGene; payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from BeiGene, Merck Sharp & Dohme and Pierre Fabre Oncology; and support for attending meetings and\/or travel from Merck Sharp & Dohme, Novartis and BeiGene. G.M. reports payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from AstraZeneca, Roche, Merck Sharp & Dohme, Terumo and Sirtex; support for attending meetings and\/or travel from Amgen, Takeda Pharmaceutical and Servier; and participation on a data safety monitoring board or an advisory board for Roche. D.S. has nothing to disclose. T.-Y.K. reports grants or contracts from AstraZeneca and consulting fees from Boryung and BeiGene. M.M. is an employee of Astellas Pharma. A.S. was an employee of Astellas Pharma at the time of this study. M.Z. is an employee of Astellas Pharma. J.H. is an employee of Astellas Pharma. A.G. is an employee of Astellas Pharma. X.W. is an employee of Astellas Pharma. A.Z. reports consulting fees from Amgen, Merck Serono, Sanofi, Merck Sharp & Dohme, Servier, Astellas Pharma, Bristol Myers Squibb GmbH & Co. KG, Pierre Fabre, AstraZeneca, Daiichi-Sankyo, BeiGene, AbbVie, Gilead Sciences and Jazz Pharmaceuticals; has received support for travel or accommodation from Servier, Merck Sharp & Dohme, Pierre Fabre, Amgen, Merck, Jazz Pharmaceuticals and Astellas Pharma; and has received research funding from Amgen. S.J.K. reports consulting fees from Astellas Pharma, Merck, Gilead, BeiGene, I-Mab, Elevation Oncology, AstraZeneca, Daiichi-Sankyo, Amgen, Eisai, Taiho Oncology and Bristol Myers Squibb; payment or honoraria for Gastric Cancer Lecture in 2023 from Merck; participation on a data safety monitoring board or an advisory board for Sanofi-Aventis; stock options from MBrace Therapeutics (no value, private company); National Comprehensive Cancer Network guidelines panel member (not compensated); continuing medical education participation for Research to Practice (payment provided to S.J.K.); medical advisory board member for Debbie\u2019s Dream Foundation (not compensated); and medical advisory board member for Hope for Stomach Cancer (not compensated).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}